Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 23, 2021 (5 years ago)

Lyrica CR (pregabalin)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-count bottles, Rx only, Distributed by Parke-Davis Division of Pfizer Inc., NY, NY 10017, NDC 0071-1029-01

Affected NDC 0071-1029-01

Compare with the code on your package — it is the most precise check available.

Drug: Pregabalin

Recalling firm
Viatris
NDC code
0071-1029-01
Origin
WV, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0851-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Pregabalin recalls

See all
Class III · Low risk

Pregabalin Capsules 50mg

Presence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was discovered in one of the bottles during packaging set up. Tablet identified as pantoprazole tablet 20mg.

Ongoing Particulate / foreign matter Rising Pharma Holding, Inc. NDC 64980-411-10 D-0541-2024
Class II · Moderate risk

Pregabalin Capsules

Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient.

Terminated Failed specification Sun Pharmaceutical Industries INC NDC 47335-687-88 D-0361-2022
Class II · Moderate risk

LYRICA (pregabalin)

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. D-0552-2021
Class II · Moderate risk

Lyrica (pregabalin)

FAILED TABLET/CAPSULE SPECIFICATIONS: Firm is recalling specific lots of pregabalin capsules due to the potential presence of deformed or damaged capsules.

Terminated Failed specification Pfizer Inc. NDC 0071-1014-68 D-0649-2016

Other recalls by Viatris

All 2021 recalls
Class II · Moderate risk

Xanax XR

Failed Dissolution Specifications

Ongoing Dissolution failure Viatris, Inc. NDC 58151-506-91 D-0444-2026
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

Terminated Impurity / degradation Viatris Inc NDC 58151-078-93 D-0204-2025
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

Terminated Impurity / degradation Viatris Inc NDC 58151-079-93 D-0203-2025